Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 10
Submit an article Journal homepage
298
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment

Sandy AmorimHémato-Oncologie, AP-HP – Hôpital Saint-Louis (SLS), Paris, France; ;Université Paris Diderot, Sorbonne Paris Cité, Paris, France;
,
Isabelle FleuryHémato-Oncologie, AP-HP – Hôpital Saint-Louis (SLS), Paris, France;
,
Nicolas MounierCHU De l'Archet – Hemato-Oncologie, Nice, France
,
Stéphanie HarelHémato-Oncologie, AP-HP – Hôpital Saint-Louis (SLS), Paris, France; ;Université Paris Diderot, Sorbonne Paris Cité, Paris, France;
,
Pauline BriceHémato-Oncologie, AP-HP – Hôpital Saint-Louis (SLS), Paris, France;
&
Catherine ThieblemontHémato-Oncologie, AP-HP – Hôpital Saint-Louis (SLS), Paris, France; ;Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Correspondence[email protected]
Pages 2425-2428 | Received 01 Sep 2015, Accepted 16 Dec 2015, Published online: 11 Jan 2016

References

  • Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540–1545.
  • Thieblemont C, Gisselbrecht C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep. 2009;11:386–393.
  • Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190.
  • Lignon J, Sibon D, Madelaine I, et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:262–269.
  • Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858–1867.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th Ed. Lyon, France: IARC WHO Press, 2008.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Van Den Neste E, Gisselbrecht C, Schmitz N, et al. Diffuse large B-cell lymphoma (DLBCL) patients failing second-line R-DHAP or R-ICE chemotherapy included in the coral study. Blood. 2013;122:764–764.
  • Beaven AW, Rizzieri D. Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Invest. 2011;2:49–58.
  • Mukherji D, Pettengell R. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Expert Opin Pharmacother. 2010;11:1915–1923.
  • Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952–4957.
  • Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622–1627.
  • Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11:462–466.
  • Matasar MJ, Czuczman MS, Rodriguez MA, et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 2013;122:499–506.
  • Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922–926.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.